Literature DB >> 9359731

Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms.

C M Mason1, E Dobard, W R Summer, S Nelson.   

Abstract

Translocation of enteric bacteria or their components (or both) has been postulated to play a role in precipitating sepsis or the systemic inflammatory response syndrome. To simulate the effects of translocation on pulmonary host defenses, lipopolysaccharide was injected into the portal vein of normal rats that were subsequently challenged by aerosol inoculation with Pseudomonas aeruginosa. Injection of LPS into the portal vein resulted in increased serum tumor necrosis factor (TNF)-alpha levels and reduction in lung clearance of P. aeruginosa after aerosol challenge. There were corresponding reductions in alveolar neutrophil recruitment, diminished alveolar macrophage phagocytosis and superoxide anion (O2-) production, and diminished lung TNF recovered by bronchoalveolar lavage. Furthermore, prior intravenous injection of recombinant TNF-alpha reproduced the defective bacterial clearance, the altered recruitment of airspace neutrophils, and the defective alveolar macrophage phagocytosis. Thus, systemic TNF-alpha is important in altering pulmonary defenses, and this work supports the concept that bacterial translocation may adversely affect host defenses in distant organs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359731     DOI: 10.1086/514125

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Effects of Aging on Inflammation and Hemostasis through the Continuum of Critical Illness.

Authors:  Sachin S Kale; Sachin Yende
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

2.  Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials.

Authors:  R D'Amico; S Pifferi; C Leonetti; V Torri; A Tinazzi; A Liberati
Journal:  BMJ       Date:  1998-04-25

3.  When host defense goes awry: Modeling sepsis-induced immunosuppression.

Authors:  Scott B Hu; Alexander Zider; Jane C Deng
Journal:  Drug Discov Today Dis Models       Date:  2012

4.  Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom.

Authors:  Junko Takeshita; Daniel B Shin; Alexis Ogdie; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-03-02       Impact factor: 8.551

5.  Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia.

Authors:  Sachin Yende; Elaine I Tuomanen; Richard Wunderink; Alka Kanaya; Anne B Newman; Tamara Harris; Nathalie de Rekeneire; Stephen B Kritchevsky
Journal:  Am J Respir Crit Care Med       Date:  2005-09-15       Impact factor: 21.405

6.  Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection.

Authors:  N Rayhane; C Fitting; O Lortholary; F Dromer; J M Cavaillon
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  An explanation for the paradoxical induction and suppression of an acute phase response by ethanol.

Authors:  Brandon S Pruett; Stephen B Pruett
Journal:  Alcohol       Date:  2006-10-02       Impact factor: 2.405

Review 8.  The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.

Authors:  Julia K Bohannon; Antonio Hernandez; Perenlei Enkhbaatar; William L Adams; Edward R Sherwood
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

9.  Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo.

Authors:  Charay Jennings; Brenda Kusler; Patricia P Jones
Journal:  Innate Immun       Date:  2009-04       Impact factor: 2.680

10.  Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis.

Authors:  Derek S Wheeler; Patrick M Lahni; Alvin G Denenberg; Sue E Poynter; Hector R Wong; James A Cook; Basilia Zingarelli
Journal:  Shock       Date:  2008-09       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.